BIBAX

What this means for you

Not registered yet, but its 24 Jan 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

97766160

Mark type

Stylized text

Filed

24 Jan 2023

Attorney of record

Nicholas D. Wells

Goods and services

• Class 005 — Pharmaceuticals: Medical and veterinary preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment and prevention of human infectious diseases; biomedical pharmaceutical products for the treatment and prevention of human infectious diseases; clinical diagnostic reagents; therapeutic agents being Therapeutic vaccines; prophylactical agent substances, namely, pharmaceutical preparations for the prevention of infectious diseases; medicine being Medicinal preparations for the treatment of infectious diseases and for use in; biological and chemical reagents, for medical and veterinary uses; agonists for medical and veterinary uses, namely, namely, pharmaceutical preparations for the treatment and prevention of human infectious diseases; medicines for veterinary purposes for the treatment and prevention of infectious diseases; amino acids for medical or veterinary purposes; antibacterial pharmaceuticals; anti-bacterial preparations; antibacterial substances for medical purposes; antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; antibodies, namely, monoclonal antibodies for in vivo or clinical use; antitoxins; antiviral drugs for treating influenza; antiviral drugs for treating hiv; anti-viral agents, namely, anti-viral antigens being pharmaceutical preparations for the treatment and prevention of infectious diseases; autoantigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; biological adjuvants for medical purposes; endogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; exogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; human immune globulin for the treatment and prevention of cancer and infectious diseases; human vaccine preparations; immunomodulators; immunostimulants; vaccines against flu; immunotherapeutic agents for bacterial infections; anti-infective goods for medical and veterinary uses; medicated mouth spray; medicated nasal spray preparations; anti-malarials; neoantigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical products for treating respiratory diseases, pharmaceutical products for the treatment of infectious diseases, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of disorders caused by bacteria, pharmaceutical preparations for the treatment of diseases caused by bacteria, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of disorders of the immune system; anti-infectives; anti- tuberculous preparations; tumour antigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; viral antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; viral vaccines; veterinary vaccines; vaccines; mrna and vector-based vaccines; protein-based vaccines
• Class 042 — Scientific and technological services: Provision of information and data in the field of medical and veterinary research and development, namely, in the fields of immunology, infectiology and vaccines; research and design for the pharmaceutical industry, namely in the fields of immunology, infectiology and vaccines; biomedical research services; research and development in the field of vaccines; software development and research in the fields of infectiology and immunology; research and development of biomolecules, cells and cell products for medical purposes; research and development of biomedical goods, in particular therapeutic and prophylactic substances, namely, pharmaceuticals for medical purposes, and preparations for the treatment of Coronaviridae, including SARS-CoV-2 and MERS-CoV, Flaviviridae including Dengue, hepatitis, yellow fever, and Zika virus, Herpesviridae including EBV, Orthomyxoviridae including Influenzaviruses, and Filoviridae; medical laboratory services; computer diagnostic services

Owner

• de la Rosa, Kathrin, Berlin, DE

Prosecution history

• 16 Jun 2026 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
• 16 Jun 2026 — INQUIRY TO SUSPENSION E-MAILED
• 16 Jun 2026 — SUSPENSION INQUIRY WRITTEN
• 16 Jun 2026 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 16 Dec 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 16 Dec 2025 — LETTER OF SUSPENSION E-MAILED
• 16 Dec 2025 — SUSPENSION LETTER WRITTEN
• 16 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 16 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 10 Nov 2025 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
• 09 Sept 2025 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
• 09 Sept 2025 — INQUIRY TO SUSPENSION E-MAILED
• 09 Sept 2025 — SUSPENSION INQUIRY WRITTEN
• 06 Aug 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 04 Feb 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED